Outer Membrane Vesicle Vaccine Platforms.

Journal

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

ISSN: 1179-190X

Titre abrégé: BioDrugs

Pays: New Zealand

ID NLM: 9705305

Informations de publication

Date de publication:
05 Oct 2023

Historique:

accepted: 19 09 2023

medline: 5 10 2023

pubmed: 5 10 2023

entrez: 5 10 2023

Statut: aheadofprint

Résumé

Outer membrane vesicles (OMVs) are spontaneously released by many gram-negative bacteria during their growth and constitute an important virulence factor for bacteria, helping them to survive through harsh environmental conditions. Native OMVs, naturally-released from bacteria, are produced at a level too low for vaccine manufacturing, requiring chemical treatment (detergent-extracted) or genetic manipulation, resulting in generalized modules for membrane antigens (GMMAs). Over the years, the nature and properties of OMVs have made them a viable platform for vaccine development. There are a few licensed OMV vaccines mainly for the prevention of meningitis caused by Neisseria meningitidis serogroup B (MenB) and Haemophilus influenzae type b (Hib). There are several candidates in clinical development against other gram-negative organisms from which the OMVs are derived, but also against heterologous targets in which the OMVs are used as carriers (e.g. coronavirus disease 2019 [COVID-19]). The use of OMVs for targets other than those from which they are derived is a major advancement in OMV technology, improving its versatility by being able to deliver protein or polysaccharide antigens. Other advances include the range of genetic modifications that can be made to improve their safety, reduce reactogenicity, and increase immunogenicity and protective efficacy. However, significant challenges remain, such as identification of general tools for high-content surface expression of heterologous proteins on the OMV surface. Here, we outline the progress of OMV vaccines to date, particularly discussing licensed OMV-based vaccines and candidates in clinical development. Recent trends in preclinical research are described, mainly focused on genetic manipulation and chemical conjugation for the use of OMVs as carriers for heterologous protein and polysaccharide antigens. Remaining challenges with the use of OMVs and directions for future research are also discussed.

Identifiants

DOI: 10.1007/s40259-023-00627-0 PMID: 37796436

pubmed: 37796436

doi: 10.1007/s40259-023-00627-0

pii: 10.1007/s40259-023-00627-0

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

McBroom AJ, Johnson AP, Vemulapalli S, Kuehn MJ. Outer membrane vesicle production by Escherichia coli is independent of membrane instability. J Bacteriol. 2006;188(15):5385–92. https://doi.org/10.1128/jb.00498-06 .

doi: 10.1128/jb.00498-06 pubmed: 16855227 pmcid: 1540050

van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10(11):1689–706. https://doi.org/10.1002/biot.201400395 .

doi: 10.1002/biot.201400395 pubmed: 26912077 pmcid: 4768646

Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74(1):81–94. https://doi.org/10.1128/mmbr.00031-09 .

doi: 10.1128/mmbr.00031-09 pubmed: 20197500 pmcid: 2832350

Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13(10):605–19. https://doi.org/10.1038/nrmicro3525 .

doi: 10.1038/nrmicro3525 pubmed: 26373371 pmcid: 5308417

Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13–24. https://doi.org/10.1038/s41579-018-0112-2 .

doi: 10.1038/s41579-018-0112-2 pubmed: 30397270

DeVoe IW, Gilchrist JE. Pili on meningococci from primary cultures of nasopharyngeal carriers and cerebrospinal fluid of patients with acute disease. J Exp Med. 1975;141(2):297–305. https://doi.org/10.1084/jem.141.2.297 .

doi: 10.1084/jem.141.2.297 pubmed: 803544

Schooling SR, Beveridge TJ. Membrane vesicles: an overlooked component of the matrices of biofilms. J Bacteriol. 2006;188(16):5945–57. https://doi.org/10.1128/jb.00257-06 .

doi: 10.1128/jb.00257-06 pubmed: 16885463 pmcid: 1540058

Palsdottir H, Remis JP, Schaudinn C, O’Toole E, Lux R, Shi W, et al. Three-dimensional macromolecular organization of cryofixed Myxococcus xanthus biofilms as revealed by electron microscopic tomography. J Bacteriol. 2009;191(7):2077–82. https://doi.org/10.1128/jb.01333-08 .

doi: 10.1128/jb.01333-08 pubmed: 19168614 pmcid: 2655519

Kadurugamuwa JL, Beveridge TJ. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol. 1995;177(14):3998–4008. https://doi.org/10.1128/jb.177.14.3998-4008.1995 .

doi: 10.1128/jb.177.14.3998-4008.1995 pubmed: 7608073 pmcid: 177130

Rumbo C, Fernández-Moreira E, Merino M, Poza M, Mendez JA, Soares NC, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–90. https://doi.org/10.1128/aac.00929-10 .

doi: 10.1128/aac.00929-10 pubmed: 21518847 pmcid: 3122458

Mancini F, Rossi O, Necchi F, Micoli F. OMV vaccines and the role of TLR agonists in immune response. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21124416 .

doi: 10.3390/ijms21124416 pubmed: 33276425 pmcid: 7730996

Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50: 101433. https://doi.org/10.1016/j.smim.2020.101433 .

doi: 10.1016/j.smim.2020.101433 pubmed: 33309166

Piccioli D, Bartolini E, Micoli F. GMMA as a “plug and play” technology to tackle infectious disease to improve global health: context and perspectives for the future. Expert Rev Vaccines. 2022;21(2):163–72. https://doi.org/10.1080/14760584.2022.2009803 .

doi: 10.1080/14760584.2022.2009803 pubmed: 34913415

Gnopo YMD, Watkins HC, Stevenson TC, DeLisa MP, Putnam D. Designer outer membrane vesicles as immunomodulatory systems—reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017;114:132–42. https://doi.org/10.1016/j.addr.2017.05.003 .

doi: 10.1016/j.addr.2017.05.003 pubmed: 28501509

Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–21. https://doi.org/10.1080/14760584.2018.1547637 .

doi: 10.1080/14760584.2018.1547637 pubmed: 30457407

Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, Biolchi A, et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics. 2006;6(6):1856–66. https://doi.org/10.1002/pmic.200500164 .

doi: 10.1002/pmic.200500164 pubmed: 16456881

van de Waterbeemd B, Mommen GP, Pennings JL, Eppink MH, Wijffels RH, van der Pol LA, et al. Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. J Proteome Res. 2013;12(4):1898–908. https://doi.org/10.1021/pr301208g .

doi: 10.1021/pr301208g pubmed: 23410224

Bernadac A, Gavioli M, Lazzaroni JC, Raina S, Lloubes R. Escherichia coli tol-pal mutants form outer membrane vesicles. J Bacteriol. 1998;180(18):4872–8.

doi: 10.1128/JB.180.18.4872-4878.1998 pubmed: 9733690 pmcid: 107512

Turner L, Praszkier J, Hutton ML, Steer D, Ramm G, Kaparakis-Liaskos M, et al. Increased outer membrane vesicle formation in a Helicobacter pylori tolB mutant. Helicobacter. 2015;20(4):269–83. https://doi.org/10.1111/hel.12196 .

doi: 10.1111/hel.12196 pubmed: 25669590

Mitra S, Sinha R, Mitobe J, Koley H. Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain. Vaccine. 2016;34(15):1839–46. https://doi.org/10.1016/j.vaccine.2016.02.018 .

doi: 10.1016/j.vaccine.2016.02.018 pubmed: 26878295

Schwechheimer C, Rodriguez DL, Kuehn MJ. NlpI-mediated modulation of outer membrane vesicle production through peptidoglycan dynamics in Escherichia coli. MicrobiologyOpen. 2015;4(3):375–89. https://doi.org/10.1002/mbo3.244 .

doi: 10.1002/mbo3.244 pubmed: 25755088 pmcid: 4475382

Kulp AJ, Sun B, Ai T, Manning AJ, Orench-Rivera N, Schmid AK, et al. Genome-wide assessment of outer membrane vesicle production in Escherichia coli. PLoS ONE. 2015;10(9): e0139200. https://doi.org/10.1371/journal.pone.0139200 .

doi: 10.1371/journal.pone.0139200 pubmed: 26406465 pmcid: 4583269

Roier S, Zingl FG, Cakar F, Durakovic S, Kohl P, Eichmann TO, et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun. 2016;7:10515. https://doi.org/10.1038/ncomms10515 .

doi: 10.1038/ncomms10515 pubmed: 26806181 pmcid: 4737802

Sonntag I, Schwarz H, Hirota Y, Henning U. Cell envelope and shape of Escherichia coli: multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins. J Bacteriol. 1978;136(1):280–5.

doi: 10.1128/jb.136.1.280-285.1978 pubmed: 361695 pmcid: 218658

Maharjan S, Saleem M, Feavers IM, Wheeler JX, Care R, Derrick JP. Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis. Microbiology (Reading, England). 2016;162(2):364–75. https://doi.org/10.1099/mic.0.000227 .

doi: 10.1099/mic.0.000227 pubmed: 26678687

Premjani V, Tilley D, Gruenheid S, Le Moual H, Samis JA. Enterohemorrhagic Escherichia coli OmpT regulates outer membrane vesicle biogenesis. FEMS Microbiol Lett. 2014;355(2):185–92. https://doi.org/10.1111/1574-6968.12463 .

doi: 10.1111/1574-6968.12463 pubmed: 24813639

Elhenawy W, Bording-Jorgensen M, Valguarnera E, Haurat MF, Wine E, Feldman MF. LPS remodeling triggers formation of outer membrane vesicles in Salmonella. MBio. 2016. https://doi.org/10.1128/mBio.00940-16 .

doi: 10.1128/mBio.00940-16 pubmed: 27406567 pmcid: 4958258

McMahon KJ, Castelli ME, García Vescovi E, Feldman MF. Biogenesis of outer membrane vesicles in Serratia marcescens is thermoregulated and can be induced by activation of the Rcs phosphorelay system. J Bacteriol. 2012;194(12):3241–9. https://doi.org/10.1128/jb.00016-12 .

doi: 10.1128/jb.00016-12 pubmed: 22493021 pmcid: 3370869

Sidik S, Kottwitz H, Benjamin J, Ryu J, Jarrar A, Garduno R, et al. A Shigella flexneri virulence plasmid encoded factor controls production of outer membrane vesicles. G3 (Bethesda). 2014;4(12):2493–503.

doi: 10.1534/g3.114.014381 pubmed: 25378474 pmcid: 4267944

Li Y, Wang Z, Chen J, Ernst RK, Wang X. Influence of lipid A acylation pattern on membrane permeability and innate immune stimulation. Mar Drugs. 2013;11(9):3197–208. https://doi.org/10.3390/md11093197 .

doi: 10.3390/md11093197 pubmed: 24065161 pmcid: 3806461

Han Y, Li Y, Chen J, Tan Y, Guan F, Wang X. Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharides. Mar Drugs. 2013;11(2):363–76. https://doi.org/10.3390/md11020363 .

doi: 10.3390/md11020363 pubmed: 23434832 pmcid: 3640385

Zariri A, van der Ley P. Biosynthetically engineered lipopolysaccharide as vaccine adjuvant. Expert Rev Vaccines. 2015;14(6):861–76. https://doi.org/10.1586/14760584.2015.1026808 .

doi: 10.1586/14760584.2015.1026808 pubmed: 25797360

Rossi O, Pesce I, Giannelli C, Aprea S, Caboni M, Citiulo F, et al. Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants. J Biol Chem. 2014;289(36):24922–35. https://doi.org/10.1074/jbc.M114.566570 .

doi: 10.1074/jbc.M114.566570 pubmed: 25023285 pmcid: 4155660

Rossi O, Caboni M, Negrea A, Necchi F, Alfini R, Micoli F, et al. Toll-like receptor activation by generalized modules for membrane antigens from lipid a mutants of Salmonella enterica Serovars Typhimurium and Enteritidis. Clin Vaccine Immunol. 2016;23(4):304–14. https://doi.org/10.1128/CVI.00023-16 .

doi: 10.1128/CVI.00023-16 pubmed: 26865597 pmcid: 4820502

Tondi S, Clemente B, Esposito C, Sammicheli C, Tavarini S, Martin LB, et al. Dissecting in vitro the activation of human immune response induced by Shigella sonnei GMMA. Front Cell Infect Microbiol. 2022;12: 767153. https://doi.org/10.3389/fcimb.2022.767153 .

doi: 10.3389/fcimb.2022.767153 pubmed: 35186786 pmcid: 8851470

van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001;69(10):5981–90. https://doi.org/10.1128/iai.69.10.5981-5990.2001 .

doi: 10.1128/iai.69.10.5981-5990.2001 pubmed: 11553534 pmcid: 98725

Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun. 2005;73(7):4070–80. https://doi.org/10.1128/iai.73.7.4070-4080.2005 .

doi: 10.1128/iai.73.7.4070-4080.2005 pubmed: 15972495 pmcid: 1168616

Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, et al. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine. 2014;32(23):2688–95. https://doi.org/10.1016/j.vaccine.2014.03.068 .

doi: 10.1016/j.vaccine.2014.03.068 pubmed: 24704334

Gerke C, Colucci AM, Giannelli C, Sanzone S, Vitali CG, Sollai L, et al. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS ONE. 2015;10(8): e0134478. https://doi.org/10.1371/journal.pone.0134478 .

doi: 10.1371/journal.pone.0134478 pubmed: 26248044 pmcid: 4527750

Gerritzen MJH, Salverda MLM, Martens DE, Wijffels RH, Stork M. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Vaccine. 2019;37(47):6978–86. https://doi.org/10.1016/j.vaccine.2019.01.076 .

doi: 10.1016/j.vaccine.2019.01.076 pubmed: 31383485

Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. https://doi.org/10.1016/j.vaccine.2018.12.061 .

doi: 10.1016/j.vaccine.2018.12.061 pubmed: 30661831

Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005–14. https://doi.org/10.4161/hv.29218 .

doi: 10.4161/hv.29218 pubmed: 25424810 pmcid: 4186018

Bexsero summary of product characteristics. https://www.medicines.org.uk/emc/product/5168/smpc .

Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. https://doi.org/10.1056/NEJMoa1901229 .

doi: 10.1056/NEJMoa1901229 pubmed: 31971676

Burton C, Best E, Broom M, Heffernan H, Briggs S, Webb R. Pediatric invasive meningococcal disease, Auckland, New Zealand (Aotearoa), 2004–2020. Emerg Infect Dis. 2023;29(4):686–95. https://doi.org/10.3201/eid2904.221397 .

doi: 10.3201/eid2904.221397 pubmed: 36957984 pmcid: 10045698

Arnold R, Galloway Y, McNicholas A, O’Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–6. https://doi.org/10.1016/j.vaccine.2011.06.120 .

doi: 10.1016/j.vaccine.2011.06.120 pubmed: 21803101

Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–6. https://doi.org/10.1016/0140-6736(91)91961-s .

doi: 10.1016/0140-6736(91)91961-s pubmed: 1682541

Caron F, du Châtelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–63. https://doi.org/10.1016/s1473-3099(11)70027-5 .

doi: 10.1016/s1473-3099(11)70027-5 pubmed: 21489881

Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207 (discussion 8–10).

pubmed: 1812432

Sierra-González VG. Cuban meningococcal vaccine VA-MENGOC-BC: 30 years of use and future potential. MEDICC Rev. 2019;21(4):19–27. https://doi.org/10.37757/mr2019.V21.N4.4 .

doi: 10.37757/mr2019.V21.N4.4 pubmed: 32335565

Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324(25):1767–72. https://doi.org/10.1056/nejm199106203242503 .

doi: 10.1056/nejm199106203242503 pubmed: 1903846

Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992;121(2):187–94. https://doi.org/10.1016/s0022-3476(05)81186-2 .

doi: 10.1016/s0022-3476(05)81186-2 pubmed: 1640282

Recommendations for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria T, Pertussis, and Haemophilus b Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 42(RR-13). Publication date: 17 Sep 1993.

Procomvax summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/procomvax-epar-product-information_en.pdf .

Comvax summary of product characteristics. https://www.drugs.com/pro/comvax-vaccine.html .

Vaxelis summary of product characteristics. https://www.medicines.org.uk/emc/product/12264/smpc .

Gilsdorf JR. Hib vaccines: their impact on haemophilus influenzae type b disease. J Infect Dis. 2021;224(12 Suppl 2):S321–30. https://doi.org/10.1093/infdis/jiaa537 .

doi: 10.1093/infdis/jiaa537 pubmed: 34590133 pmcid: 8482018

Schager AE, Dominguez-Medina CC, Necchi F, Micoli F, Goh YS, Goodall M, et al. IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal Salmonella develop at discordant rates. MBio. 2018. https://doi.org/10.1128/mBio.02379-17 .

doi: 10.1128/mBio.02379-17 pubmed: 29511082 pmcid: 5844998

De Benedetto G, Alfini R, Cescutti P, Caboni M, Lanzilao L, Necchi F, et al. Characterization of O-antigen delivered by generalized modules for membrane antigens (GMMA) vaccine candidates against nontyphoidal Salmonella. Vaccine. 2017;35(3):419–26. https://doi.org/10.1016/j.vaccine.2016.11.089 .

doi: 10.1016/j.vaccine.2016.11.089 pubmed: 27998639

Micoli F, Nakakana UN, Berlanda SF. Towards a four-component GMMA-based vaccine against Shigella. Vaccines. 2022. https://doi.org/10.3390/vaccines10020328 .

doi: 10.3390/vaccines10020328 pubmed: 35893831 pmcid: 9331691

Micoli F, Rondini S, Alfini R, Lanzilao L, Necchi F, Negrea A, et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. Proc Natl Acad Sci USA. 2018;41(115):10428–33.

doi: 10.1073/pnas.1807655115

Micoli F, Rossi O, Conti V, Launay O, Sciré AS, Aruta MG, et al. Antibodies elicited by the Shigella sonnei GMMA vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension. Front Immunol. 2021;12: 671325. https://doi.org/10.3389/fimmu.2021.671325 .

doi: 10.3389/fimmu.2021.671325 pubmed: 34017343 pmcid: 8129577

Obiero CW, Ndiaye AGW, Scire AS, Kaunyangi BM, Marchetti E, Gone AM, et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front Immunol. 2017;8:1884. https://doi.org/10.3389/fimmu.2017.01884 .

doi: 10.3389/fimmu.2017.01884 pubmed: 29375556 pmcid: 5763125

Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Scire AS, et al. Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine. 2017;22:164–72. https://doi.org/10.1016/j.ebiom.2017.07.013 .

doi: 10.1016/j.ebiom.2017.07.013 pubmed: 28735965 pmcid: 5552227

Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, et al. Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: exploratory analysis of a Phase 2a randomized study. Front Immunol. 2022;13: 971866. https://doi.org/10.3389/fimmu.2022.971866 .

doi: 10.3389/fimmu.2022.971866 pubmed: 36203568 pmcid: 9531247

Launay O, Ndiaye AGW, Conti V, Loulergue P, Scire AS, Landre AM, et al. Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results from a phase 1 clinical trial. Front Immunol. 2019;10:335. https://doi.org/10.3389/fimmu.2019.00335 .

doi: 10.3389/fimmu.2019.00335 pubmed: 30906291 pmcid: 6418009

Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. https://doi.org/10.1016/s0140-6736(17)31449-6 .

doi: 10.1016/s0140-6736(17)31449-6 pubmed: 28705462

Whelan J, Kløvstad H, Haugen IL, Holle MR, Storsaeter J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis. 2016;22(6):1137–9. https://doi.org/10.3201/eid2206.151093 .

doi: 10.3201/eid2206.151093 pubmed: 27191543 pmcid: 4880101

Azze RFO. A meningococcal B vaccine induces cross-protection against gonorrhea. Clin Exp Vaccine Res. 2019;8(2):110–5. https://doi.org/10.7774/cevr.2019.8.2.110 .

doi: 10.7774/cevr.2019.8.2.110 pubmed: 31406692 pmcid: 6689502

Bishop AL, Schild S, Patimalla B, Klein B, Camilli A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun. 2010;78(10):4402–20. https://doi.org/10.1128/iai.00398-10 .

doi: 10.1128/iai.00398-10 pubmed: 20679439 pmcid: 2950341

Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun. 2008;76(10):4554–63. https://doi.org/10.1128/iai.00532-08 .

doi: 10.1128/iai.00532-08 pubmed: 18678672 pmcid: 2546833

Li B, Xu Y, Xu T, Guo Z, Xu Q, Li Y, et al. Disruption of sncRNA improves the protective efficacy of outer membrane vesicles against Helicobacter pylori infection in a mouse model. Infect Immun. 2022;90(8): e0026722. https://doi.org/10.1128/iai.00267-22 .

doi: 10.1128/iai.00267-22 pubmed: 35861532

Liu Q, Liu Q, Yi J, Liang K, Hu B, Zhang X, et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Sci Rep. 2016;6:34776. https://doi.org/10.1038/srep34776 .

doi: 10.1038/srep34776 pubmed: 27698383 pmcid: 5048178

Chen Y, Jie K, Li B, Yu H, Ruan H, Wu J, et al. Immunization with outer membrane vesicles derived from major outer membrane protein-deficient salmonella typhimurium mutants for cross protection against Salmonella Enteritidis and avian pathogenic Escherichia coli O78 infection in chickens. Front Microbiol. 2020;11: 588952. https://doi.org/10.3389/fmicb.2020.588952 .

doi: 10.3389/fmicb.2020.588952 pubmed: 33329465 pmcid: 7720508

Bartolini E, Ianni E, Frigimelica E, Petracca R, Galli G, Berlanda Scorza F, et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J Extracell Vesicles. 2013. https://doi.org/10.3402/jev.v2i0.20181 .

doi: 10.3402/jev.v2i0.20181 pubmed: 24009891 pmcid: 3760637

Fantappiè L, de Santis M, Chiarot E, Carboni F, Bensi G, Jousson O, et al. Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracellular Vesicles. 2014. https://doi.org/10.3402/jev.v3.24015 .

doi: 10.3402/jev.v3.24015

Kesty NC, Kuehn MJ. Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem. 2004;279(3):2069–76. https://doi.org/10.1074/jbc.M307628200 .

doi: 10.1074/jbc.M307628200 pubmed: 14578354

Kim SH, Kim KS, Lee SR, Kim E, Kim MS, Lee EY, et al. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochem Biophys Acta. 2009;1788(10):2150–9. https://doi.org/10.1016/j.bbamem.2009.08.001 .

doi: 10.1016/j.bbamem.2009.08.001 pubmed: 19695218

Muralinath M, Kuehn MJ, Roland KL, Curtiss R 3rd. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun. 2011;79(2):887–94. https://doi.org/10.1128/iai.00950-10 .

doi: 10.1128/iai.00950-10 pubmed: 21115718

Schild S, Nelson EJ, Bishop AL, Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun. 2009;77(1):472–84. https://doi.org/10.1128/iai.01139-08 .

doi: 10.1128/iai.01139-08 pubmed: 19001078

Salverda ML, Meinderts SM, Hamstra HJ, Wagemakers A, Hovius JW, van der Ark A, et al. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles. Vaccine. 2016;34(8):1025–33. https://doi.org/10.1016/j.vaccine.2016.01.019 .

doi: 10.1016/j.vaccine.2016.01.019 pubmed: 26801064

Necchi F, Stefanetti G, Alfini R, Palmieri E, Carducci M, Di Benedetto R, et al. Neisseria meningitidis factor H binding protein surface exposure on Salmonella typhimurium GMMA Is critical to induce an effective immune response against both diseases. Pathogens (Basel, Switzerland). 2021. https://doi.org/10.3390/pathogens10060726 .

Alfini R, Brunelli B, Bartolini E, Carducci M, Luzzi E, Ferlicca F, et al. Investigating the role of antigen orientation on the immune response elicited by Neisseria meningitidis factor H binding protein on GMMA. Vaccines. 2022. https://doi.org/10.3390/vaccines10081182 .

doi: 10.3390/vaccines10081182 pubmed: 35893831 pmcid: 9331691

Georgiou G, Segatori L. Preparative expression of secreted proteins in bacteria: status report and future prospects. Curr Opin Biotechnol. 2005;16(5):538–45. https://doi.org/10.1016/j.copbio.2005.07.008 .

doi: 10.1016/j.copbio.2005.07.008 pubmed: 16095898

Jong WS, Daleke-Schermerhorn MH, Vikström D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, et al. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Fact. 2014;13:162. https://doi.org/10.1186/s12934-014-0162-8 .

doi: 10.1186/s12934-014-0162-8 pubmed: 25421093 pmcid: 4252983

Daleke-Schermerhorn MH, Felix T, Soprova Z, Ten Hagen-Jongman CM, Vikstrom D, Majlessi L, et al. Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach. Appl Environ Microbiol. 2014;80(18):5854–65. https://doi.org/10.1128/aem.01941-14 .

doi: 10.1128/aem.01941-14 pubmed: 25038093 pmcid: 4178611

Kuipers K, Daleke-Schermerhorn MH, Jong WS, ten Hagen-Jongman CM, van Opzeeland F, Simonetti E, et al. Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. Vaccine. 2015;33(17):2022–9. https://doi.org/10.1016/j.vaccine.2015.03.010 .

doi: 10.1016/j.vaccine.2015.03.010 pubmed: 25776921

Kim JY, Doody AM, Chen DJ, Cremona GH, Shuler ML, Putnam D, et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol. 2008;380(1):51–66. https://doi.org/10.1016/j.jmb.2008.03.076 .

doi: 10.1016/j.jmb.2008.03.076 pubmed: 18511069 pmcid: 4617544

Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci USA. 2010;107(7):3099–104. https://doi.org/10.1073/pnas.0805532107 .

doi: 10.1073/pnas.0805532107 pubmed: 20133740 pmcid: 2840271

Huang W, Wang S, Yao Y, Xia Y, Yang X, Li K, et al. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep. 2016;6:37242. https://doi.org/10.1038/srep37242 .

doi: 10.1038/srep37242 pubmed: 27849050 pmcid: 5110958

van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol. 2021;12: 781280. https://doi.org/10.3389/fimmu.2021.781280 .

doi: 10.3389/fimmu.2021.781280 pubmed: 34987509 pmcid: 8721663

Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, et al. Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine. Res Square. 2023. https://doi.org/10.21203/rs.3.rs-2788726/v1 .

doi: 10.21203/rs.3.rs-2788726/v1

Shehata MM, Mostafa A, Teubner L, Mahmoud SH, Kandeil A, Elshesheny R, et al. Bacterial outer membrane vesicles (OMVs)-based dual vaccine for Influenza A H1N1 virus and MERS-CoV. Vaccines. 2019. https://doi.org/10.3390/vaccines7020046 .

doi: 10.3390/vaccines7020046 pubmed: 31141982 pmcid: 6631769

Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA. 2012;109(12):E690–7. https://doi.org/10.1073/pnas.1115485109 .

doi: 10.1073/pnas.1115485109 pubmed: 22366317 pmcid: 3311370

Alves NJ, Turner KB, Daniele MA, Oh E, Medintz IL, Walper SA. Bacterial nanobioreactors-directing enzyme packaging into bacterial outer membrane vesicles. ACS Appl Mater Interfaces. 2015;7(44):24963–72. https://doi.org/10.1021/acsami.5b08811 .

doi: 10.1021/acsami.5b08811 pubmed: 26479678

van den Berg van Saparoea HB, Houben D, Kuijl C, Luirink J, Jong WSP. Combining protein ligation systems to expand the functionality of semi-synthetic outer membrane vesicle nanoparticles. Front Microbiol. 2020;11:890. https://doi.org/10.3389/fmicb.2020.00890 .

Jiang L, Driedonks TAP, Jong WSP, Dhakal S, Bart van den Berg van Saparoea H, Sitaras I, et al. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. J Extracellular Vesicles. 2022;11(3):e12192. https://doi.org/10.1002/jev2.12192 .

Weyant KB, Oloyede A, Pal S, Liao J, Jesus MR, Jaroentomeechai T, et al. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens. Nat Commun. 2023;14(1):464. https://doi.org/10.1038/s41467-023-36101-2 .

doi: 10.1038/s41467-023-36101-2 pubmed: 36709333 pmcid: 9883832

Di Benedetto R, Alfini R, Carducci M, Aruta MG, Lanzilao L, Acquaviva A, et al. Novel simple conjugation chemistries for decoration of GMMA with heterologous antigens. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms221910180 .

doi: 10.3390/ijms221910180 pubmed: 34830421 pmcid: 8618618

Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, et al. GMMA is a versatile platform to design effective multivalent combination vaccines. Vaccines. 2020. https://doi.org/10.3390/vaccines8030540 .

doi: 10.3390/vaccines8030540 pubmed: 32957610 pmcid: 7564227

Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, et al. Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230. NPJ Vaccines. 2019;4:24. https://doi.org/10.1038/s41541-019-0121-9 .

doi: 10.1038/s41541-019-0121-9 pubmed: 31312527 pmcid: 6614402

Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA. 2006;103(48):18243–8. https://doi.org/10.1073/pnas.0608545103 .

doi: 10.1073/pnas.0608545103 pubmed: 17110440 pmcid: 1636993

Hu K, Palmieri E, Samnuan K, Ricchetti B, Oldrini D, McKay PF, et al. Generalized modules for membrane antigens (GMMA), an outer membrane vesicle-based vaccine platform, for efficient viral antigen delivery. J Extracellular Vesicles. 2022;11(11): e12247. https://doi.org/10.1002/jev2.12247 .

doi: 10.1002/jev2.12247

Donnelly JJ, Deck RR, Liu MA. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol. 1990;145(9):3071–9.

doi: 10.4049/jimmunol.145.9.3071 pubmed: 2120344

Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol. 2004;172(4):2431–8. https://doi.org/10.4049/jimmunol.172.4.2431 .

doi: 10.4049/jimmunol.172.4.2431 pubmed: 14764714

Adamo R, Feron C. Conjugated haemophilus influenzae vaccine using Bordetella outer membrane vesicle. Immunogenic conjugates. WIPO Patent Application WO2020043874. Application no. PCT/EP2019/073195 (2019).

Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, et al. Generalized modules for membrane antigens as carrier for polysaccharides: impact of sugar length, density, and attachment site on the immune response elicited in animal models. Front Immunol. 2021;12: 719315. https://doi.org/10.3389/fimmu.2021.719315 .

doi: 10.3389/fimmu.2021.719315 pubmed: 34594333 pmcid: 8477636

Raso MM, Gasperini G, Alfini R, Schiavo F, Aruta MG, Carducci M, et al. GMMA and glycoconjugate approaches compared in mice for the development of a vaccine against Shigella flexneri serotype 6. Vaccines. 2020. https://doi.org/10.3390/vaccines8020160 .

doi: 10.3390/vaccines8020160 pubmed: 32260067 pmcid: 7349896

Palmieri E, Kis Z, Ozanne J, Di Benedetto R, Ricchetti B, Massai L, et al. GMMA as an alternative carrier for a glycoconjugate vaccine against Group A Streptococcus. Vaccines. 2022. https://doi.org/10.3390/vaccines10071034 .

doi: 10.3390/vaccines10071034 pubmed: 35891202 pmcid: 9324507

Gasperini G, Alfini R, Arato V, Mancini F, Aruta MG, Kanvatirth P, et al. Salmonella paratyphi a outer membrane vesicles displaying vi polysaccharide as a multivalent vaccine against enteric fever. Infect Immunity. 2021. https://doi.org/10.1128/iai.00699-20 .

doi: 10.1128/iai.00699-20

Piccioli D, Alfini R, Monaci V, Arato V, Carducci M, Aruta MG, et al. Antigen presentation by follicular dendritic cells to cognate b cells is pivotal for generalised modules for membrane antigens (GMMA) immunogenicity. Vaccine. 2022;40(44):6305–14. https://doi.org/10.1016/j.vaccine.2022.09.034 .

doi: 10.1016/j.vaccine.2022.09.034 pubmed: 36137901

Valguarnera E, Feldman MF. Glycoengineered outer membrane vesicles as a platform for vaccine development. Meth Enzymol. 2017;597:285–310. https://doi.org/10.1016/bs.mie.2017.06.032 .

doi: 10.1016/bs.mie.2017.06.032

Chen L, Valentine JL, Huang C-J, Endicott CE, Moeller TD, Rasmussen JA, et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proceed Natl Acad Sci USA. 2016:E3609–E18. https://doi.org/10.1073/pnas.1518311113 .

Price NL, Goyette-Desjardins G, Nothaft H, Valguarnera E, Szymanski CM, Segura M, et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci Rep. 2016;6:24931. https://doi.org/10.1038/srep24931 .

doi: 10.1038/srep24931 pubmed: 27103188 pmcid: 4840304

Stevenson TC, Cywes-Bentley C, Moeller TD, Weyant KB, Putnam D, Chang Y-F, et al. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc Natl Acad Sci USA. 2018;115(8):E3106–15.

pubmed: 29555731 pmcid: 5889644

Tian H, Li B, Xu T, Yu H, Chen J, Yu H, et al. Outer membrane vesicles derived from salmonella enterica serotype typhimurium can deliver Shigella flexneri 2a O-polysaccharide antigen to prevent Shigella flexneri 2a infection in mice. Appl Environ Microbiol. 2021;87(19): e0096821. https://doi.org/10.1128/aem.00968-21 .

doi: 10.1128/aem.00968-21 pubmed: 34319809

Outer Membrane Vesicle Vaccine Platforms.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Francesca Micoli (F)

Roberto Adamo (R)

Usman Nakakana (U)

Classifications MeSH